Literature DB >> 17697260

ESDN is a marker of vascular remodeling and regulator of cell proliferation in graft arteriosclerosis.

M M Sadeghi1, L Esmailzadeh, J Zhang, X Guo, A Asadi, S Krassilnikova, H R Fassaei, G Luo, R S M Al-Lamki, T Takahashi, G Tellides, J R Bender, E R Rodriguez.   

Abstract

Vascular remodeling is a common feature of many vasculopathies, including graft arteriosclerosis (GA). We investigated whether endothelial and smooth muscle cell-derived neuropilin-like protein (ESDN) is a marker of vascular remodeling in GA. Immunostaining of human coronary arteries demonstrated high levels of ESDN in GA, but not in normal arteries. In a model of GA, where a segment of human coronary is transplanted into a severe combined immunodeficient mouse, followed by allogeneic human peripheral blood mononuclear cell (PBMC) reconstitution, ESDN was minimally expressed in transplanted human arteries in the absence of reconstitution. By 2 weeks following PBMC reconstitution, at a time corresponding to maximal vascular cell proliferation, high levels of ESDN were detected in the transplanted arteries. Similarly, injury-induced vascular remodeling in apoE(-/-) mice was associated with early and transient ESDN upregulation, in parallel with cell proliferation. In vascular smooth muscle cell (VSMC) cultures, ESDN expression was significantly higher in proliferating, as compared to growth-arrested cells. ESDN overexpression in VSMC led to a decline in growth curves, while ESDN knock down had the opposite effect. We conclude that ESDN is a marker of vascular remodeling and regulator of VSMC proliferation. ESDN may serve as a therapeutic or diagnostic target for GA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17697260     DOI: 10.1111/j.1600-6143.2007.01919.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  13 in total

1.  VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling.

Authors:  Jiasheng Zhang; Teresa Silva; Timur Yarovinsky; Thomas D Manes; Sina Tavakoli; Lei Nie; George Tellides; Jordan S Pober; Jeffrey R Bender; Mehran M Sadeghi
Journal:  Circ Res       Date:  2010-06-10       Impact factor: 17.367

2.  EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.

Authors:  Haizhong Feng; Giselle Y Lopez; Chung Kwon Kim; Angel Alvarez; Christopher G Duncan; Ryo Nishikawa; Motoo Nagane; An-Jey A Su; Philip E Auron; Matthew L Hedberg; Lin Wang; Jeffery J Raizer; John A Kessler; Andrew T Parsa; Wei-Qiang Gao; Sung-Hak Kim; Mutsuko Minata; Ichiro Nakano; Jennifer R Grandis; Roger E McLendon; Darell D Bigner; Hui-Kuan Lin; Frank B Furnari; Webster K Cavenee; Bo Hu; Hai Yan; Shi-Yuan Cheng
Journal:  J Clin Invest       Date:  2014-07-25       Impact factor: 14.808

3.  Transmembrane protein ESDN promotes endothelial VEGF signaling and regulates angiogenesis.

Authors:  Lei Nie; Xiaojia Guo; Leila Esmailzadeh; Jiasheng Zhang; Abolfazl Asadi; Mark Collinge; Xuan Li; Jun-Dae Kim; Melissa Woolls; Suk-Won Jin; Alexandre Dubrac; Anne Eichmann; Michael Simons; Jeffrey R Bender; Mehran M Sadeghi
Journal:  J Clin Invest       Date:  2013-11-01       Impact factor: 14.808

4.  Endothelial and smooth muscle-derived neuropilin-like protein regulates platelet-derived growth factor signaling in human vascular smooth muscle cells by modulating receptor ubiquitination.

Authors:  Xiaojia Guo; Lei Nie; Leila Esmailzadeh; Jiasheng Zhang; Jeffrey R Bender; Mehran M Sadeghi
Journal:  J Biol Chem       Date:  2009-08-19       Impact factor: 5.157

5.  Tyrosine phosphorylation of the orphan receptor ESDN/DCBLD2 serves as a scaffold for the signaling adaptor CrkL.

Authors:  Tyler M Aten; Miranda M Redmond; Sheila O Weaver; Collin C Love; Ryan M Joy; Aliya S Lapp; Osvaldo D Rivera; Karen L Hinkle; Bryan A Ballif
Journal:  FEBS Lett       Date:  2013-06-13       Impact factor: 4.124

6.  Potential association of DCBLD2 polymorphisms with fall rates of FEV(1) by aspirin provocation in Korean asthmatics.

Authors:  Tae-Joon Park; Jeong-Hyun Kim; Byung-Lae Park; Hyun Sub Cheong; Joon Seol Bae; Charisse F Pasaje; Jong-Sook Park; Soo-Taek Uh; Mi-Kyeong Kim; Inseon S Choi; Choon-Sik Park; Hyoung Doo Shin
Journal:  J Korean Med Sci       Date:  2012-03-21       Impact factor: 2.153

7.  Novel Transcript Discovery Expands the Repertoire of Pathologically-Associated, Long Non-Coding RNAs in Vascular Smooth Muscle Cells.

Authors:  Matthew Bennett; Igor Ulitsky; Iraide Alloza; Koen Vandenbroeck; Vladislav Miscianinov; Amira Dia Mahmoud; Margaret Ballantyne; Julie Rodor; Andrew H Baker
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

8.  A homozygous nonsense mutation in DCBLD2 is a candidate cause of developmental delay, dysmorphic features and restrictive cardiomyopathy.

Authors:  Kheloud M Alhamoudi; Tlili Barhoumi; Hamad Al-Eidi; Abdulaziz Asiri; Marwan Nashabat; Manal Alaamery; Masheal Alharbi; Yazeid Alhaidan; Brahim Tabarki; Muhammad Umair; Majid Alfadhel
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

9.  Dynamic multi-site phosphorylation by Fyn and Abl drives the interaction between CRKL and the novel scaffolding receptors DCBLD1 and DCBLD2.

Authors:  Anna M Schmoker; Jaye L Weinert; Kyle J Kellett; Hannah E Johnson; Ryan M Joy; Marion E Weir; Alicia M Ebert; Bryan A Ballif
Journal:  Biochem J       Date:  2017-11-21       Impact factor: 3.857

10.  The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19.

Authors:  Camila Rosat Consiglio; Nicola Cotugno; Fabian Sardh; Christian Pou; Donato Amodio; Lucie Rodriguez; Ziyang Tan; Sonia Zicari; Alessandra Ruggiero; Giuseppe Rubens Pascucci; Veronica Santilli; Tessa Campbell; Yenan Bryceson; Daniel Eriksson; Jun Wang; Alessandra Marchesi; Tadepally Lakshmikanth; Andrea Campana; Alberto Villani; Paolo Rossi; Nils Landegren; Paolo Palma; Petter Brodin
Journal:  Cell       Date:  2020-09-06       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.